Record mula sa primary source

MateryalPagbabago sa trial registry

Olema Oncology: on track for palazestrant OPERA-01 Phase 3 topline in Q1 2027

Ang quarterly update na ito ay muling nagpapatunay na ang pivotal Phase 3 OPERA-01 trial ng palazestrant ay nananatiling on track upang iulat ang top-line data sa Q1 2027. Itinatala rin nito ang patuloy na malakas na enrollment sa pivotal Phase 3 OPERA-02 trial ng palazestrant plus ribociclib.

Mahahalagang fact

Na-file
Set 30, 2026, 12:00 PM
Kaganapan
Pagbabago sa trial registry
Direksyon
Neutral
Kumpanya
OLMAOlema
Pinagmulan
SEC 8-K
Kumpiyansa
May source

Sipi mula sa source

EX-99.1 2 olma-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Olema Oncology Reports Third Quarter 2026 Financial and Operating Results • On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027 • Continued strong enrollment in the pivotal Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136 • Appointed Jason O’Byrne, MBA, as Chief Financial Officer • Ended the third quarter with $413.8 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, November 10, 2026 (Globe NewsWire) – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported

SEC 8-K

Higit pa tungkol sa asset na ito

Nob 20, 2026
03:25 PM
OLMAOlema

palazestrant · NCT07085767 update sa rehistro

Pagbabago sa trial registryClinicalTrials.gov
Set 23, 2026
03:23 PM
OLMAOlema

palazestrant · NCT07085767 update ng registry

Pagbabago sa trial registryClinicalTrials.gov
Ene 12, 2026
09:44 PM
OLMAOlema

Ina-update ng Olema ang mga timeline ng OPERA-01/02 Phase 3 para sa palazestrant

Pagbabago sa trial registrySEC 8-K
Okt 20, 2025
09:13 PM
OLMAOlema

Olema naglalahad ng palazestrant + ribociclib Phase 1b/2 data sa ESMO 2025

Presentasyon sa kumperensyaSEC 8-K
Olema Oncology: on track for palazestrant OPERA-01 Phase 3 topline in Q1 2027 | SimianX AI